US Pneumococcal Vaccine Market Size Worth $6,511.79 million by 2034 | CAGR: 2.3%

The US pneumococcal vaccine market size is expected to reach USD 6,511.79 million by 2034, according to a new study by Polaris Market Research. The report “US Pneumococcal Vaccine Market Size, Share, Trend, Industry Analysis Report, By Vaccine Type, By Product Type (Prevnar 13, Synflorix, Pneumovax23), By End User, Market Forecast, 2025 - 2034” gives a detailed insight into current market dynamics and provides analysis of future market growth.

The increasing number of patients with pneumonia in the US presents an opportunity for biotechnology companies to develop new pneumonia vaccines, which will contribute significantly to the growth of the US pneumococcal vaccine market.

The introduction of new drugs approved by the USFDA helps drive the market forward. For example, in May 2024, the FDA approved licenses for pneumococcal vaccines for use in the US, including Pneumovax 23, Prevnar 13, VAXNEUVANCE, and Prevnar 20. Pharmacists are well-positioned to provide recommendations for appropriate pneumococcal vaccinations, taking into account a patient's risk factors and vaccination history. Pharmacists are authorized to administer vaccines and assess patients to ensure they receive the appropriate vaccinations. To assist in making recommendations, pharmacists can use resources such as the CDC's mobile application, PneumoRecs VaxAdvisor.The increasing number of patients with pneumonia diseases in the US creates an opportunity for the biotechnology company to develop new pneumonia vaccines that significantly contribute to the US pneumococcal vaccine market growth.

For instance, in April 2024, Merck revealed positive data from the Phase III STRIDE-10 trial of V116, an investigational pneumococcal conjugate vaccine.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/us-pneumococcal-vaccine-market/request-for-sample

Ongoing innovation in pneumococcal vaccine formulations aims to improve efficacy and broaden protection against more strains of pneumococcal bacteria, including the development of next-generation conjugate vaccines that target additional serotypes (bacterial strains), offering enhanced immune response and longer-lasting protection. Companies such as Pfizer and Merck are working on new formulations that address emerging strains and reduce the risk of invasive pneumococcal diseases in vulnerable populations, such as children and old people. These innovations also aim to reduce dosing schedules, making vaccination more convenient and effective in large-scale immunization programs.

US Pneumococcal Vaccine Market Report Highlights

• Prevnar 13 is the dominant pneumococcal vaccine in the United States by product type due to its broad protection against 13 strains of Streptococcus pneumonia, including those most commonly associated with severe infections.
• The pneumococcal conjugate vaccine (PCV) segment is expected to witness the highest growth over the study period, owing to the increasing number of pneumococcal diseases.
• The public sector dominates pneumococcal vaccine administration due to government immunization programs, widespread public healthcare infrastructure, and funding that ensures accessible, cost-effective vaccination. Disease prevention mandates further prioritize its use in hospitals and clinics.
• The US pneumococcal vaccine market players are Pfizer Inc.; Merck & Co., Inc.; Novavax, Inc.; CSL Behring; and Johnson & Johnson.

Market Research has segmented the US pneumococcal vaccine market report based on vaccine type, product type, and end user:

By Vaccine Type Outlook (Revenue - USD Million, 2020 - 2034)

• Pneumococcal conjugate vaccine
• Pneumococcal polysaccharide vaccine

By Product Type Outlook (Revenue - USD Million, 2020 - 2034)

• Prevnar 13
• Synflorix
• Pneumovax23

By End User Outlook (Revenue - USD Million, 2020 - 2034)

• Public Sector 
• Private Sector

US Pneumococcal Vaccine Market Report Scope